With ACO REACH ending this year, every organization in it faces the same fork — and so does any group finally ready to take on accountable care: LEAD or the Medicare Shared Savings Program? They are not interchangeable. They reward different organizations, on different timelines, with different risk.

One honest timing note first: the first LEAD cohort’s application window (the RFA closed May 17, 2026) has passed, with selections announced this summer and a January 1, 2027 launch. So for many organizations, this is less “apply now” and more “understand the landscape you’re choosing your next move within.”

Start with risk appetite, not features

MSSP lets you wade in. LEAD asks you to swim.

MSSP’s BASIC track includes upside-only levels (A and B) before escalating to two-sided risk along a glide path; the ENHANCED track is the highest risk and reward. LEAD is two-sided from day one — Professional (50%) or Global (up to 100%).

If your organization needs a genuine on-ramp to learn risk before bearing it, MSSP still offers one. LEAD does not.

Payment model and cash flow

MSSP is fundamentally a retrospective shared-savings program. LEAD pays prospectively through capitation (Primary Care or Total Care), which materially improves cash flow for organizations investing up front in care management.

If your binding constraint is capital to build infrastructure, that difference is not cosmetic.

The benchmark horizon

MSSP rebases benchmarks each agreement period — the ratchet that penalizes your own past success. LEAD removes rebasing for ten years.

For a high-performing ACO that expects to keep lowering cost, this is arguably the most important line in the comparison. For an organization not yet generating savings, it matters less.

Population fit

LEAD was built around high-needs, dual-eligible, rural, and complex-care populations, with lower alignment minimums (40% high-needs panels) and concurrent risk adjustment. If that is your population, LEAD’s design is pointed at you.

If you are a broad primary-care base looking for a stable, permanent program with predictable rules, MSSP’s permanence is itself a feature — it is not a time-limited demonstration.

Permanence vs. horizon — a real tradeoff

One is permanent but resets; the other is finite but stable.

MSSP is statutory and ongoing; it will outlast LEAD’s 2036 sunset. LEAD offers a longer uninterrupted horizon without rebasing but is, ultimately, a ten-year model test.

Neither is strictly safer. The question is whether you value a permanent program with periodic benchmark resets, or a decade of stable benchmarks in a model that ends in 2036.

Final Thoughts

The reflex to pick the “more advanced” model is a mistake. The right answer depends on your risk capacity, your capital position, your population, and how much savings you actually expect to generate.

Having advised organizations across both shared-savings and capitated structures, the pattern I see is simple: high-performing, complex-care, or cash-constrained organizations often fit LEAD; organizations needing an on-ramp or valuing permanence often fit MSSP. Run the comparison against your own numbers before the next decision window — not the brochure.

If your REACH agreement is ending and “LEAD vs. MSSP” is an open question on your strategy table, the answer is specific to your population and balance sheet. At HealtheNomics, we help organizations run that comparison against their actual data and risk tolerance.

Explore the services: https://healthenomics.com/services-2/

Request a strategy conversation: https://healthenomics.com/contact-us/

Connect on LinkedIn: https://www.linkedin.com/in/muhammad-ayoub-ashraf/

Website: https://www.drayoubashraf.com

Watch on YouTube: https://www.youtube.com/@HealtheNomics